Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer

Oncologist

Volumn 17, Issue 12, 2012, Pages 1496-1503

  Kimple, Randall J ^a   Horton, Janet K ^b   Livasy, Chad A ^c,d   Shields, Janiel M ^c,d   Lawrence, Julia A ^b   Chiu, Wingkeung M ^d   Ivanova, Anastasia ^d,e   Ollila, David W ^c,d   Carey, Lisa A ^c,d   Halle, Jan S ^c,d   Sartor, Carolyn I ^c,d   Claire Dees, E ^c,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

Biological markers; Breast neoplasms; Combined modality therapy; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ACNE; ADULT; AGED; ARTICLE; BIOPSY; BREAST CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHEDEMA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORAL MUCOSITIS; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RADIATION DERMATITIS; RADIATION DOSE; SIGNAL TRANSDUCTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84871577219     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0256     Document Type: Article

References (33)

1. Halverson KJ, Perez CA, Kuske RR et al. Isolated local-regional recurrence of breast cancer following mastectomy: Radiotherapeutic management. Int J Radiat Oncol Biol Phys 1990;19:851-858.
2. Aberizk WJ, Silver B, Henderson IC et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986;58:1214-1218.
3. Bedwinek J. Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 1994;4:260-269.
4. van Tienhoven G, Voogd AC, Peterse JL et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). Eur J Cancer 1999;35:32-38.
5. Bedwinek JM, Fineberg B, Lee J et al. Analysis of failures following local treatment of isolated local-regional recurrence of breast cancer. Int J Radiat Oncol Biol Phys 1981;7:581-585.
6. Suh WW, Schott AF, Hayman JA et al. A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences. Breast J 2004;10:204-210.
7. Horton JK, Halle J, Ferraro M et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: A phase II trial. Int J Radiat Oncol Biol Phys 2010;76:998-1004.
8. Kosma L, Koukourakis M, Skarlatos J et al. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer. Am J Clin Oncol 1997;20:562-566.
9. Vujaskovic Z, Kim DW, Jones E, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia, 2010;26:514-521.
10. Sartor CI. Epidermal growth factor family receptors and inhibitors: Radiation response modulators. Semin Radiat Oncol 2003;13:22-30.
11. Harari PM, Allen GW, Bonner JA. Biology of interactions: Antiepidermal growth factor receptor agents. J Clin Oncol 2007;25:4057-4065.
12. Alaoui-Jamali MA, Paterson J, Al Moustafa AE et al. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 1997;75:315-325.
13. Sambade MJ, Camp JT, Kimple RJ et al. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf_MEK_ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 2009;93:639-644.
14. Zhou H, Kim YS, Peletier A et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFRand HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004;58:344-352.
15. Sambade MJ, Kimple RJ, Camp JT et al. Lapatinib in combination with radiation diminishes tumor regrowth in HER2_ and basal-like/EGFR_ breast tumor xenografts. Int J Radiat Oncol Biol Phys 2010;77:575-581.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Eisenhauer EA, O'Dwyer PJ, Christian M et al. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000;18:684-692.
18. McCarty KS Jr, Szabo E, Flowers JL et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46:4244s-4248s.
19. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
20. Harrington KJ, El-Hariry IA, Holford CS et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27: 1100-1107.
21. Schwaibold F, Fowble BL, Solin LJ et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991;21:299-310.
22. Mendenhall NP, Devine JW, Mendenhall WM et al. Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiother Oncol 1988;12:177-185.
23. Schuck A, Konemann S, Matthees B et al. Radiotherapy in the treatment of locoregional relapses of breast cancer. Br J Radiol 2002;75:663-669.
24. Ballo MT, Strom EA, Prost H et al. Local-regional control of recurrent breast carcinoma after mastectomy: Does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys 1999; 44:105-112.
25. Huang E, McNeese MD, Strom EA et al. Locoregional treatment outcomes for inoperable anthracyclineresistant breast cancer. Int J Radiat Oncol Biol Phys 2002;53:1225-1233.
26. Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996; 35:731-744.
27. Formenti SC, Volm M, Skinner KA et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: A phase I/II trial. J Clin Oncol 2003;21:864-870.
28. Chakravarthy AB, Kelley MC, McLaren B et al. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res 2006;12:1570-1576.
29. Lacouture ME, Laabs SM, Koehler M et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009; 114:485-493.
30. Burris HA 3rd, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-5313.
31. Crown JP, Burris HA 3rd, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;112:317-325.
32. Brown AP, Wendler DS, Camphausen KA et al. Performing nondiagnostic research biopsies in irradiated tissue: A review of scientific, clinical, and ethical considerations. J Clin Oncol 2008;26:3987-3994.
33. Spector NL, Xia W, Burris H et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005;23:2502-2512.